Progressive Thinning of Retinal Nerve Fiber Layer and Ganglion Cell-Inner Plexiform Layer in Glaucoma Eyes with Disc Hemorrhage.
Circumpapillary retinal nerve fiber layer
Disc hemorrhage
Macular ganglion cell–inner plexiform layer
OCT
Primary open-angle glaucoma
Journal
Ophthalmology. Glaucoma
ISSN: 2589-4196
Titre abrégé: Ophthalmol Glaucoma
Pays: United States
ID NLM: 101730510
Informations de publication
Date de publication:
Historique:
received:
02
11
2020
revised:
13
01
2021
accepted:
21
01
2021
pubmed:
3
2
2021
medline:
29
10
2021
entrez:
2
2
2021
Statut:
ppublish
Résumé
To evaluate the thinning of the circumpapillary retinal nerve fiber layer (cpRNFL) and macular ganglion cell-inner plexiform layer (mGCIPL) in primary open-angle glaucoma eyes with and without a history of disc hemorrhage (DH). Observational cohort study. Thirty-nine 39 eyes (34 participants) with DH and 117 eyes (104 participants) without DH from the Diagnostic Innovations in Glaucoma Study and the African Decent and Glaucoma Evaluation Study. Participants had at least 1.5 years of follow-up, with a minimum of 3 visits with biannual spectral-domain OCT cpRNFL and mGCIPL thickness measurements and visual fields (VFs). The rates of cpRNFL and mGCIPL thinning were calculated using mixed-effects models. The dynamic range-based normalized rates of cpRNFL and mGCIPL thinning were calculated and compared between the DH and non-DH groups. Rates of cpRNFL and mGCIPL thinning. The rate of mGCIPL thinning was significantly faster in the DH group compared with the non-DH group (-0.62 μm/year vs. -0.38 μm/year; P = 0.024). The rate of cpRNFL thinning in the DH quadrant and rate of mGCIPL thinning in the inferotemporal sector in the DH group were faster than the corresponding regions in the non-DH group after adjusting for intraocular pressure (-1.33 μm/year vs. -0.58 μm/year; P = 0.053) and race (-0.82 μm/year vs. -0.44 μm/year; P = 0.048). In the DH group, percent rate of loss was significantly faster for the mGCIPL than the cpRNFL (-1.59 %/year vs. -1.31 %/year; P = 0.046). Rates of mGCIPL thinning were associated weakly with mean deviation slope, VF index slope, and guided progression analysis (GPA). The areas under the receiver operating characteristic curve for VF progression were 0.75 for mGCIPL and 0.56 for cpRNFL in the DH group. The rate of mGCIPL and cpRNFL thinning was faster in DH eyes than non-DH eyes. Compared with cpRNFL, mGCIPL showed higher proportional rates of thinning and greater association with functional progression. In addition to cpRNFL, clinicians should consider incorporating mGCIPL imaging to monitor glaucoma progression, especially in glaucoma eyes with DH.
Identifiants
pubmed: 33529795
pii: S2589-4196(21)00031-4
doi: 10.1016/j.ogla.2021.01.003
pmc: PMC8322143
mid: NIHMS1668443
pii:
doi:
Types de publication
Journal Article
Observational Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
541-549Subventions
Organisme : NEI NIH HHS
ID : R01 EY011008
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY029058
Pays : United States
Organisme : NEI NIH HHS
ID : P30 EY022589
Pays : United States
Organisme : NEI NIH HHS
ID : K08 EY033032
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY019869
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY027510
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY014267
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY026574
Pays : United States
Informations de copyright
Copyright © 2021 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Références
Ophthalmology. 1998 Feb;105(2):224-31
pubmed: 9479279
Ophthalmology. 2013 May;120(5):969-77
pubmed: 23399380
J Glaucoma. 2017 Oct;26(10):888-895
pubmed: 28991833
Invest Ophthalmol Vis Sci. 2010 Nov;51(11):5724-30
pubmed: 20574014
Ophthalmology. 1995 Mar;102(3):365-6
pubmed: 7891969
Invest Ophthalmol Vis Sci. 2013 Jul 01;54(7):4422-9
pubmed: 23722389
J Glaucoma. 2020 Jun;29(6):429-434
pubmed: 32287146
Ophthalmology. 2012 Feb;119(2):308-13
pubmed: 22182800
Arch Ophthalmol. 1997 Oct;115(10):1257-62
pubmed: 9338670
PLoS One. 2016 Aug 18;11(8):e0160549
pubmed: 27537107
J Glaucoma. 2012 Aug;21(6):358-66
pubmed: 21623225
J Glaucoma. 2017 Feb;26(2):126-132
pubmed: 27820423
Ophthalmology. 2016 Jul;123(7):1476-83
pubmed: 27117781
Ophthalmology. 2008 Nov;115(11):2044-8
pubmed: 18692244
Prog Retin Eye Res. 2013 Jan;32:1-21
pubmed: 22995953
J Glaucoma. 2016 Feb;25(2):e76-81
pubmed: 25943726
Ophthalmology. 2020 Aug;127(8):1043-1052
pubmed: 32085875
Ophthalmology. 2018 Jul;125(7):1003-1013
pubmed: 29486903
Invest Ophthalmol Vis Sci. 2015 Jul;56(8):4857-64
pubmed: 25829417
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(9):OCT511-8
pubmed: 27454660
Arch Ophthalmol. 2009 Sep;127(9):1136-45
pubmed: 19752422
JAMA. 2014 May 14;311(18):1901-11
pubmed: 24825645
Am J Ophthalmol. 2001 Jun;131(6):699-708
pubmed: 11384564
Graefes Arch Clin Exp Ophthalmol. 2012 Apr;250(4):583-7
pubmed: 21947302
Ophthalmology. 2017 Sep;124(9):1403-1411
pubmed: 28499748
PLoS One. 2014 Aug 26;9(8):e105611
pubmed: 25157619
Invest Ophthalmol Vis Sci. 2011 Oct 21;52(11):8323-9
pubmed: 21917932
J Glaucoma. 2014 Oct-Nov;23(8):547-52
pubmed: 25093520
Ophthalmology. 2006 Dec;113(12):2137-43
pubmed: 16996592
Am J Ophthalmol. 2017 Jun;178:38-50
pubmed: 28315655
Ophthalmology. 2012 Jun;119(6):1151-8
pubmed: 22365056
Ophthalmology. 2010 Nov;117(11):2061-6
pubmed: 20541265
Invest Ophthalmol Vis Sci. 2001 Aug;42(9):1993-2003
pubmed: 11481263
Ophthalmology. 2018 Dec;125(12):1907-1912
pubmed: 29934267
J Comp Neurol. 1990 Oct 1;300(1):5-25
pubmed: 2229487